| Literature DB >> 28599746 |
Naiara S Barbosa1, David A Wetter1, Carilyn N Wieland2, Niraj K Shenoy3, Svetomir N Markovic4, Uma Thanarajasingam5.
Abstract
Immune checkpoint inhibitors are approved for select cancer treatment and have shown survival benefit in patients with advanced melanoma. Adverse events, including immune-related adverse events, are common and potentially life-threatening. We describe cases of 2 patients with scleroderma (patient 1 had diffuse scleroderma, and patient 2 had limited scleroderma) that developed while they were receiving pembrolizumab therapy for metastatic melanoma. Prompt recognition and treatment of immune-related adverse events may improve tolerance to immune checkpoint inhibitors and contribute to an understanding of the manifesting autoimmune disease.Entities:
Mesh：
Substances：
Year: 2017 PMID： 28599746 DOI： 10.1016/j.mayocp.2017.03.016
Source DB: PubMed Journal: Mayo Clin Proc ISSN： 0025-6196 Impact factor: 7.616